医学
耐火材料(行星科学)
淋巴瘤
弥漫性大B细胞淋巴瘤
肿瘤科
内科学
疾病
重症监护医学
天体生物学
物理
出处
期刊:Journal of The National Comprehensive Cancer Network
日期:2021-11-01
卷期号:19 (11.5): 1327-1330
被引量:1
标识
DOI:10.6004/jnccn.2021.5109
摘要
Despite a growing therapeutic arsenal to treat relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), outcomes remain poor. Only approximately half of patients with this disease are eligible to receive curative autologous stem cell transplant, and of those, only half will be cured. Moreover, for patients who are transplant-ineligible, there are few effective options. Dr. Matthew J. Matasar discussed the current unmet needs in the treatment of patients with R/R DLBCL, treatment strategies in the second- and third-line settings, and emerging therapeutic options.
科研通智能强力驱动
Strongly Powered by AbleSci AI